According to Reuters on April 26th, the US government has accused British American Tobacco (BAT) of selling tobacco products to North Korea from 2007 to 2017, resulting in a fine of $635 million for the company. This could make it difficult for BAT to gain more popularity in the US market.
However, for this tobacco giant with a value of 82 billion dollars, paying a settlement of 635 million dollars plus interest may not cause a great financial loss. Although the investigation is ongoing, British American Tobacco confirmed a reserve of 450 million pounds last July and maintained that the final amount of the fine would not affect its annual profit expectations.
Despite this, investors still expect BAT to shift its listing location to the United States to narrow the valuation gap. According to data from Refinitiv, although British American Tobacco has higher profit growth, its current price-to-earnings ratio is only 8 times, compared to its US-listed peer Philip Morris International (PMI) with a ratio of 16 times. However, the reputation damage caused by fines has increased the risk of moving to the United States, and even if they do move, US investors may still discount its valuation.
Reference:
Sanctions hurt British American Tobacco's (BAT) hopes for a US listing.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
